The purpose of this study is to find out what effects, good and/or bad, the combination of
sorafenib and dacarbazine has on sarcoma. Recurrent sarcoma is difficult to treat. Standard
chemotherapy drugs can be toxic, and the length of benefit is usually short. As a result, we
need new treatments for sarcoma. Sorafenib is a new type of "targeted" chemotherapy that
attacks specific proteins (including "raf" and "VEGF receptor") in cells. We hope that by
blocking these proteins we can cause the tumor to shrink. Sorafenib is also known as BAY
43-9006 and by the trade name Nexavar®. The FDA approved sorafenib in December of 2005 to
treat patients with kidney cancer and in November of 2007 to treat patients with liver
cancer. This drug is not approved by the U.S. Food and Drug Administration (FDA) or any other
licensing authority for the treatment of sarcoma and is therefore considered to be
experimental in this setting.